Longo G, Poli F, Ventura A, Marchesi E
Clinica Pediatrica, Ospedale Infantile Burlo Garofolo, Università di Trieste.
Minerva Pediatr. 1990 May;42(5):179-83.
The use of loratadine was compared to dexchlorpheniramine in the treatment of children affected by perennial allergic rhinitis in order to assess its clinical efficacy and tolerability. Children were randomly assigned to two groups: 15 were treated with loratadine and 16 with dexchlorpheniramine. Loratadine was administered in a single daily dose of 5 mg (2.5 mg for children under 20 kg) and dexchlorpheniramine at a dose of 1 mg every 8 hours (0.5 mg for the youngest children). Clinical symptoms were recorded before and during the study using a score of 0.3 (from absent to severe). Symptoms were markedly reduced by both drugs. Eye burning was reduced more by loratadine (p less than 0.05) than the control drug. Rhinoscopic investigations revealed that both groups reacted favourably to the drugs used. Overall clinical assessment showed similar and revealed the good efficacy of both drugs. Tolerability was satisfactory and there were no signs of drowsiness. Hematological and hematochemical parameters showed no clinically significant changes and body weight remained constant. On the basis of these results, loratadine is preferable to dexchlorpheniramine thanks to its once-a-day dosing.
为评估氯雷他定的临床疗效和耐受性,将其与右氯苯那敏用于治疗常年性变应性鼻炎患儿。患儿被随机分为两组:15例接受氯雷他定治疗,16例接受右氯苯那敏治疗。氯雷他定每日单次给药,剂量为5mg(20kg以下儿童为2.5mg),右氯苯那敏剂量为每8小时1mg(最小儿童为0.5mg)。在研究前和研究期间使用0 - 3分(从无到严重)记录临床症状。两种药物均使症状明显减轻。氯雷他定使眼烧灼感减轻程度大于对照药物(p<0.05)。鼻镜检查显示两组对所用药物反应良好。总体临床评估显示相似结果,表明两种药物疗效均佳。耐受性良好,无嗜睡迹象。血液学和血液生化参数无临床显著变化,体重保持恒定。基于这些结果,由于氯雷他定每日一次给药,故优于右氯苯那敏。